Salomon & Ludwin’s Biogen BIIB Stock Holding History

Salomon & Ludwin’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1K	Hold	57	–	–	﹤0.01%	1519
2025 Q4	$9.95K	Hold	57	–	–	﹤0.01%	1442
2025 Q3	$9.11K	Buy	+57	New	+$7.71K	﹤0.01%	1381

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Salomon & Ludwin's BIIB Position: Q1 2026 in Review

Salomon & Ludwin held its Biogen (BIIB) position steady in Q1 2026 at 57 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1519.

Salomon & Ludwin first reported a position in BIIB in Q3 2025 and has held it in 3 quarters since. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Salomon & Ludwin held 57 shares of Biogen worth $10.1K as of Q1 2026.
Salomon & Ludwin left its Biogen share count unchanged in Q1 2026.
Biogen made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1519 holding.
Salomon & Ludwin first reported a position in Biogen in Q3 2025 and has held it in 3 quarters since.
1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.